We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Intuitive Surgical (ISRG) Well Poised on Procedural Business
Read MoreHide Full Article
On Aug 29, we issued an updated research report on Sunnyvale-based Intuitive Surgical Inc. (ISRG - Free Report) – manufacturer of the da Vinci surgical system (an advanced robot-assisted surgical system) and related instruments and accessories. The company currently carries a Zacks Rank #3 (Hold).
Among major positives, Intuitive Surgical has had an impressive run in the bourse of late. A glimpse at the recent price performance reveals a favorable return of 43.9% over the past year, comparing favorably with the industry’s increase of 4.1%. The company has a solid track characterized by consecutive earnings beat in the trailing four quarters.
In recent times, Intuitive Surgical reported stellar performance mainly due to the growing adoption of the da Vinci system among physicians and overall growth in global procedures. The da Vinci surgical system enables minimally invasive surgery that helps avoid the trauma associated with open surgery. Performance was also aided by growing volumes, courtesy to general surgery, oncology, urology and gynecology procedures.
Intuitive Surgical continuously introduces technologies for surgical systems. The company also plans to launch an upgrade – da Vinci X – to its flagship Vinci Xi technology. In this regard, management confirmed the submission of documents for CE Mark approval of Vinci X. Furthermore, the company expects availability of this device in Europe by the end of 2017. In the long haul, extensive expenditure on product pipeline and expansion in international markets like Europe should drive growth for the company.
On the flipside, the company expects procedure growth rate to slow down a bit outside the United States in the coming quarters. The long sale and purchase order cycle of the da Vinci system has added to the woes. Also, expenses on research and development (R&D) increased significantly in the first half of 2017, reflecting high spending on advanced imaging, advanced instrumentation and next-generation robotics.
Key Picks
A few better-ranked medical stocks are IDEXX Laboratories, Inc. (IDXX - Free Report) , Lantheus Holdings, Inc. (LNTH - Free Report) and Edwards Lifesciences Corporation (EW - Free Report) . Edwards Lifesciences sports a Zacks Rank #1 (Strong Buy), while Lantheus Holdings and IDEXX Laboratories carry a Zacks Rank #2 (Buy). You can see the complete list of today’s Zacks #1 Rank stocks here.
IDEXX Laboratories has a long-term expected earnings growth rate of 19.8%. The stock has gained around 6.2% over the last six months.
Lantheus Holdings has a long-term expected earnings growth rate of 12.5%. The stock has surged 34.9% over the last six months.
Edwards Lifesciences has a long-term expected earnings growth rate of 15.2%. The stock has rallied roughly 19.1% over the last six months.
4 Surprising Tech Stocks to Keep an Eye On
Tech stocks have been a major force behind the market’s record highs, but picking the best ones to buy can be tough. There’s a simple way to invest in the success of the entire sector. Zacks has just released a Special Report revealing one thing tech companies literally cannot function without. More importantly, it reveals 4 top stocks set to skyrocket on increasing demand for these devices. I encourage you to get the report now – before the next wave of innovations really takes off.
Image: Bigstock
Intuitive Surgical (ISRG) Well Poised on Procedural Business
On Aug 29, we issued an updated research report on Sunnyvale-based Intuitive Surgical Inc. (ISRG - Free Report) – manufacturer of the da Vinci surgical system (an advanced robot-assisted surgical system) and related instruments and accessories. The company currently carries a Zacks Rank #3 (Hold).
Among major positives, Intuitive Surgical has had an impressive run in the bourse of late. A glimpse at the recent price performance reveals a favorable return of 43.9% over the past year, comparing favorably with the industry’s increase of 4.1%. The company has a solid track characterized by consecutive earnings beat in the trailing four quarters.
In recent times, Intuitive Surgical reported stellar performance mainly due to the growing adoption of the da Vinci system among physicians and overall growth in global procedures. The da Vinci surgical system enables minimally invasive surgery that helps avoid the trauma associated with open surgery. Performance was also aided by growing volumes, courtesy to general surgery, oncology, urology and gynecology procedures.
Intuitive Surgical continuously introduces technologies for surgical systems. The company also plans to launch an upgrade – da Vinci X – to its flagship Vinci Xi technology. In this regard, management confirmed the submission of documents for CE Mark approval of Vinci X. Furthermore, the company expects availability of this device in Europe by the end of 2017. In the long haul, extensive expenditure on product pipeline and expansion in international markets like Europe should drive growth for the company.
On the flipside, the company expects procedure growth rate to slow down a bit outside the United States in the coming quarters. The long sale and purchase order cycle of the da Vinci system has added to the woes. Also, expenses on research and development (R&D) increased significantly in the first half of 2017, reflecting high spending on advanced imaging, advanced instrumentation and next-generation robotics.
Key Picks
A few better-ranked medical stocks are IDEXX Laboratories, Inc. (IDXX - Free Report) , Lantheus Holdings, Inc. (LNTH - Free Report) and Edwards Lifesciences Corporation (EW - Free Report) . Edwards Lifesciences sports a Zacks Rank #1 (Strong Buy), while Lantheus Holdings and IDEXX Laboratories carry a Zacks Rank #2 (Buy). You can see the complete list of today’s Zacks #1 Rank stocks here.
IDEXX Laboratories has a long-term expected earnings growth rate of 19.8%. The stock has gained around 6.2% over the last six months.
Lantheus Holdings has a long-term expected earnings growth rate of 12.5%. The stock has surged 34.9% over the last six months.
Edwards Lifesciences has a long-term expected earnings growth rate of 15.2%. The stock has rallied roughly 19.1% over the last six months.
4 Surprising Tech Stocks to Keep an Eye On
Tech stocks have been a major force behind the market’s record highs, but picking the best ones to buy can be tough. There’s a simple way to invest in the success of the entire sector. Zacks has just released a Special Report revealing one thing tech companies literally cannot function without. More importantly, it reveals 4 top stocks set to skyrocket on increasing demand for these devices. I encourage you to get the report now – before the next wave of innovations really takes off.
See Stocks Now>>